Answers are grounded in this paper and cite their sources.
Background/Objectives: Menopause is associated with symptoms that may negatively affect quality of life (QoL). This study evaluated the effects of a Hops (8-prenylnaringenin, 8-PN) and Cimicifuga-based multicomponent food supplement on menopausal symptoms and QoL in postmenopausal women. Methods: A prospective, unicentric, non-comparative, observational study was conducted in postmenopausal women aged 45–65 years with climacteric symptoms. Participants received two daily capsules (one DAY and one NIGHT) of a Hops (8-PN) and Cimicifuga-based food supplement (Libicare® Meno) for 12 weeks. QoL was assessed using the Cervantes short-form (C-SF) scale as the primary endpoint. Secondary endpoints included evaluation of general health status (EUROQOL), mood (Visual Analog Scale [VAS]), plasma vitamin D levels, satisfaction, and tolerability. Assessments were performed at baseline, 4, and 12 weeks. Results: Thirty-three women were evaluated. Total C-SF score decreased from 41.13 ± 20.2 at baseline to 36.37 ± 21.5 and 33.70 ± 18.6 at 4 and 12 weeks, respectively, reaching statistical significance at week 12 (p = 0.046). The improvement was particularly evident in the vasomotor subdomain. Mood also improved significantly, with VAS scores decreasing from 5.18 ± 2.7 to 3.12 ± 2.2 (p = 0.001) and 3.30 ± 1.9 (p < 0.001) at 4 and 12 weeks, respectively. Vitamin D levels increased from 26.57 ± 8.22 to 32.75 ± 5.65 ng/mL at week 12. No serious adverse events were reported, and 51.5% of participants were satisfied or very satisfied with treatment. Conclusions: Libicare® Meno was associated with improvements in QoL and mood in symptomatic postmenopausal women, with good tolerability and satisfaction.
No takes yet. Share an insight, caveat, or question.
Gil‐Antuñano et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: